These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25669213)

  • 1. Is the ``$1000 Genome'' really $1000? Understanding the full benefits and costs of genomic sequencing.
    Phillips KA; Pletcher MJ; Ladabaum U
    Technol Health Care; 2015; 23(3):373-9. PubMed ID: 25669213
    [No Abstract]   [Full Text] [Related]  

  • 2. Insurance for broad genomic tests in oncology.
    Eisenberg R; Varmus H
    Science; 2017 Dec; 358(6367):1133-1134. PubMed ID: 29191895
    [No Abstract]   [Full Text] [Related]  

  • 3. Exploring the benefits, harms and costs of genomic newborn screening for rare diseases.
    Baple EL; Scott RH; Banka S; Buchanan J; Fish L; Wynn S; Wilkinson D; Ellard S; MacArthur DG; Stark Z
    Nat Med; 2024 Jul; 30(7):1823-1825. PubMed ID: 38898121
    [No Abstract]   [Full Text] [Related]  

  • 4. Exome sequencing: the expert view.
    Biesecker LG; Shianna KV; Mullikin JC
    Genome Biol; 2011 Sep; 12(9):128. PubMed ID: 21920051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Getting personal.
    Nature; 2008 Oct; 455(7216):1007. PubMed ID: 18948899
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History.
    Cenin DR; Naber SK; de Weerdt AC; Jenkins MA; Preen DB; Ee HC; O'Leary PC; Lansdorp-Vogelaar I
    Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):10-21. PubMed ID: 31748260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic screening: birthright or earned with age?
    Mollison L; Berg JS
    Expert Rev Mol Diagn; 2017 Aug; 17(8):735-738. PubMed ID: 28641021
    [No Abstract]   [Full Text] [Related]  

  • 8. Genomic testing update: whole genome sequencing may be worth the money.
    Stone K
    Ann Neurol; 2012 May; 71(5):A7-9. PubMed ID: 22522489
    [No Abstract]   [Full Text] [Related]  

  • 9. Colorectal cancer screening: efficiency and effectiveness.
    Gyrd-Hansen D; Søgaard J; Kronborg O
    Health Econ; 1998 Feb; 7(1):9-20. PubMed ID: 9541080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analyses of genetic and genomic diagnostic tests.
    Payne K; Gavan SP; Wright SJ; Thompson AJ
    Nat Rev Genet; 2018 Apr; 19(4):235-246. PubMed ID: 29353875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Financial determinants of outcomes in molecular testing.
    Ross JS
    Arch Pathol Lab Med; 1999 Nov; 123(11):1071-5. PubMed ID: 10539911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic impact of medical genetic testing on clinical applications in Thailand.
    Jittikoon J; Sangroongruangsri S; Thavorncharoensap M; Chitpim N; Chaikledkaew U
    PLoS One; 2020; 15(12):e0243934. PubMed ID: 33338033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can genomics bend the cost curve?
    Armstrong K
    JAMA; 2012 Mar; 307(10):1031-2. PubMed ID: 22416096
    [No Abstract]   [Full Text] [Related]  

  • 14. The Impact of Biomarker Screening and Cascade Genetic Testing on the Cost-Effectiveness of MODY Genetic Testing.
    GoodSmith MS; Skandari MR; Huang ES; Naylor RN
    Diabetes Care; 2019 Dec; 42(12):2247-2255. PubMed ID: 31558549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Services for thalassaemia as a model for cost-benefit analysis of genetics services.
    Modell B; Kuliev AM
    J Inherit Metab Dis; 1991; 14(4):640-51. PubMed ID: 1749229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Test Pricing and Reimbursement in Genomic Medicine: Towards a General Strategy.
    Vozikis A; Cooper DN; Mitropoulou C; Kambouris ME; Brand A; Dolzan V; Fortina P; Innocenti F; Lee MT; Leyens L; Macek M; Al-Mulla F; Prainsack B; Squassina A; Taruscio D; van Schaik RH; Vayena E; Williams MS; Patrinos GP
    Public Health Genomics; 2016; 19(6):352-363. PubMed ID: 27676083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies.
    Nherera L; Marks D; Minhas R; Thorogood M; Humphries SE
    Heart; 2011 Jul; 97(14):1175-81. PubMed ID: 21685482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reply: To PMID 24957400.
    Gould-Suarez M; El-Serag HB; Musher B; Franco LM; Chen GJ
    Dig Dis Sci; 2015 Feb; 60(2):587. PubMed ID: 25756151
    [No Abstract]   [Full Text] [Related]  

  • 19. The Melanoma Genomics Managing Your Risk Study randomised controlled trial: statistical analysis plan.
    Lo SN; Smit AK; Espinoza D; Cust AE;
    Trials; 2020 Jun; 21(1):594. PubMed ID: 32605576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for Lynch syndrome: it is time to shift the focus.
    Kidambi TD; Terdiman JP
    Dig Dis Sci; 2015 Feb; 60(2):586-7. PubMed ID: 25563721
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.